Skip to Main Content

Paper Details

De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.
Cancer Cell
45
2022
BAY 2402234, DHODH, IDH, IDH mutant, IDH mutant glioma, IDH1, IDH1-mutant glioma cells, cancers, dihydroorotate, dihydroorotate dehydrogenase, glioma, glioma cells, isocitrate, isocitrate dehydrogenase, leukemia, mouse, mutant IDH, mutant IDH1, mutant IDH1-driven astrocytoma, nucleotide, patient, pyrimidine, pyrimidine nucleotide, tumor
Author NameAffiliation
Michael S ReganBrigham and Women's Hospital, Harvard Medical School
Tak W MakThe Campbell Family Institute for Breast Cancer Research, University Health Network, Canada The Princess Margaret Cancer Centre and Ontario Cancer Institute, University of Toronto
Thomas P MathewsChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center
Keith L LigonBrigham and Women's Hospital, Harvard Medical School, Dana-Farber Cancer Institute, Children's Hospital Boston
Nathalie Y R AgarBrigham and Women's Hospital, Harvard Medical School, Dana-Farber Cancer Institute
  • 1 - 5

Datasets

Release 1.2